Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Liposomes Expand Cancer Drug's Bioavailability and Potency in Mouse Model

By BiotechDaily International staff writers
Posted on 16 May 2013
Image: First author Dr. Carey Anders (Photo courtesy of the University of North Carolina, Lineberger Comprehensive Cancer Center).
Image: First author Dr. Carey Anders (Photo courtesy of the University of North Carolina, Lineberger Comprehensive Cancer Center).
Encapsulation of the anticancer drug doxorubicin (doxo) within PEGylated liposomes increased the compound's intracranial tumor bioavailability, extended its lifetime in circulation, and improved the survival rate of mice bearing intercranial triple negative breast tumors.

Investigators at the University of North Carolina (Chapel Hill, USA) sought to decrease the toxicity of doxo and increase the length of time it could circulate in the blood by enclosing the drug within PEGylated liposomes.

The investigators inoculated athymic mice intracerebrally with triple negative breast cancer cells that expressed the enzyme luciferase. They then treated some of the animals with doxo ecapslulated in PEGylated liposomes (PLD) or with free doxo (NonL-doxo). Efficacy of the treatment was assessed by survival of the animals and detection of bioluminescence.

Results published in the May 1, 2013, issue of the journal PLOS ONE revealed that treatment with PLD resulted in a 1,500-fold higher plasma and 20-fold higher intracranial tumor bioavailability compared with NonL-doxo. In addition, PLD was detected in plasma and intracranial tumors 96 hours following treatment compared to the drug being undetectable in plasma and tumors after 24 hours in the NonL-doxo animals. Survival rates for the PLD treated mice were significantly prolonged as compared NonL-doxo.

Related Links:

University of North Carolina


Channels

Genomics/Proteomics

view channel
Image: Pulsed near infrared light (shown in red) is shone onto a tumor (shown in white) that is encased in blood vessels. The tumor is imaged by photoacoustic tomography via the ultrasound emission (shown in blue) from the gold nanotubes (Photo courtesy of Jing Claussen (iThera Medical, Germany)).

Gold Nanotubes Are Novel Agents for Cancer Diagnosis and Treatment

Cancer researchers have produced a highly defined class of gold nanotubes that are suitable for use in animals as in vivo imaging nanoprobes, photothermal conversion agents, and drug delivery vehicles.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.